Literature DB >> 26468475

Drug-induced renal disorders.

Fatemeh Ghane Shahrbaf1, Farahnak Assadi2.   

Abstract

Drug-induced nephrotoxicity are more common among infants and young children and in certain clinical situations such as underlying renal dysfunction and cardiovascular disease. Drugs can cause acute renal injury, intrarenal obstruction, interstitial nephritis, nephrotic syndrome, and acid-base and fluid electrolytes disorders. Certain drugs can cause alteration in intraglomerular hemodynamics, inflammatory changes in renal tubular cells, leading to acute kidney injury (AKI), tubulointerstitial disease and renal scarring. Drug-induced nephrotoxicity tends to occur more frequently in patients with intravascular volume depletion, diabetes, congestive heart failure, chronic kidney disease, and sepsis. Therefore, early detection of drugs adverse effects is important to prevent progression to end-stage renal disease. Preventive measures requires knowledge of mechanisms of drug-induced nephrotoxicity, understanding patients and drug-related risk factors coupled with therapeutic intervention by correcting risk factors, assessing baseline renal function before initiation of therapy, adjusting the drug dosage and avoiding use of nephrotoxic drug combinations.

Entities:  

Keywords:  Acute tubular necrosis; Drugs nephrotoxicity; Hypersensitivity angeitis; Interstitial nephritis; Thrombotic microangiopathy; Tubular obstruction

Year:  2015        PMID: 26468475      PMCID: PMC4594214          DOI: 10.12861/jrip.2015.12

Source DB:  PubMed          Journal:  J Renal Inj Prev        ISSN: 2345-2781


Implication for health policy/practice/research/medical education:

Drug-induced nephrotoxicity are more common among infants and young children and in certain clinical situations such as underlying renal dysfunction and cardiovascular disease. Drugs can cause acute renal injury, intra-renal obstruction, interstitial nephritis, nephrotic syndrome, and acid-base and fluid electrolytes disorders. Early detection of drugs adverse effects is important to prevent progression to end-stage renal disease. Preventive measures requires knowledge of mechanisms of drug-induced nephrotoxicity, understanding patients and drug-related risk factors coupled with therapeutic intervention by correcting risk factors, assessing baseline renal function before initiation of therapy, adjusting the drug dosage and avoiding use of nephrotoxic drug combinations.

Introduction

Drug-induced nephrotoxicity is a common problem in clinical medicine and the incidence of drug-related acute kidney injury (AKI) may be as high as 60 percent (1-4). The condition can be costly and may require multiple interventions, including hospitalization (5). This article provides a summary of the most common mechanisms of drug-induced nephrotoxicity and prevention strategies. Pathophysiologic mechanism of drug-induced nephrotoxicity is complex and often mediated through alteration of intraglomerular hemodynamics, impaired tubular secretion, inflammation, uric acid deposition, rhabdomyolysis, and thrombotic microangiopathy (6-8). Patients with underlying renal insufficiency, defined as glomerular filtration rate (GFR) less than 60 mL/minute/1.73 m2, heart failure, sepsis, and intravascular depletion are particularly vulnerable to developing nephrotoxicity (Table 1).
Table 1

The most commonly used nephrotoxic drugs

Medication Drug category Renal toxicity
AcetaminophenNon-narcotic analgesicChronic interstitial nephritis, acute tubular necrosis
AcetazolamideCarbonic-anhydrase inhibitor Proximal renal tubular acidosis
AcyclovirAntiviralAcute interstitial nephritis, crystal nephropathy
AllopurinolHypouricemic agentAcute interstitial nephritis
AspirinNon-narcotic analgesicChronic interstitial nephritis
AmitriptylineAntidepressantRhabdomyolysis
AminoglycosidesAntimicrobialAcute tubular necrosis
Amphotericin BAntifungalAcute tubular necrosis, distal renal tubular acidosis
Angiotensin-converting enzyme inhibitors (ACEI)AntihypertensiveAcute kidney injury
Angiotensin receptor blockers (ARB)AntihypertensiveAcute kidney injury
BenzodiazepinesSedative-HypotonicRhabdomyolysis
Beta lactamsAntimicrobialAcute interstitial nephritis
CarbenicillinAntimicrobialMetabolic alkalosis
CephalosporinAntimicrobialAcute tubular necrosis
CholpropamideSulfonylureasHyponatremia, syndrome inappropriate ADH secretion
CimetidineGastrointestinalAcute interstitial nephritis
CisplatinAntineoplasticChronic interstitial nephritis
ClopidogrelAntiplateletThrombotic miroangiopathy
CocaineNarcotic analgesicRhabdomyolysis
Contrast agentsContrast mediumAcute tubular necrosis
CortisoneCorticosteroidMetabolic alkalosis, hypertension
CyclophosphamideAntineoplasticHemorrhagic cystitis
Cyclosporine ImmunosuppressiveAcute tubular necrosis, chronic interstitial nephritis, thrombotic microangiopathy
D-penicillamineAntirheumaticNephrotic syndrome
DiphenhydramineAntihistamineRhabdomyolysis
FurosemideLoop diureticAcute interstitial nephritis
GanciclovirAntiviralCrystal nephropathy
Gold Na thiomalateAniarthriticGlomerulonephritis, nephrotic syndrome
HaloperidolAntipsychoticRhabdomyolysis
IndinavirAntiviralAcute interstitial nephritis, crystal nephropathy
Interferon-alfaAntineoplasticGlomerulonephritis
LansoprazoleProton pump inhibitorAcute interstitial nephritis
LithiumAntipsychoticChronic interstitial nephritis, glomerulonephritis, rhabdomyolysis
MethadoneNarcotic analgesicRhabdomyolysis
MethamphetaminePsychostimulantRhabdomyolysis
MethotrexateAntineoplasticCrystal nephropathy
Mitomycin-CAntineoplasticThrombotic microangiopathy
NaproxenNonsteroidal anti-inflammatory Acute and chronic interstitial nephritis, acute tubular necrosis, glomerulonephritis
OmeprazoleProton pump inhibitorAcute interstitial nephritis
Pamidronate acidBisphosphonate, osteoporosis preventionGlomerulonephritis
PantoprazoleProton pump inhibitorAcute interstitial nephritis
Penicillin GpenicillinGlomerulonephritis
PentamidineAntimicrobialAcute tubular necrosis
PhenforminHypoglycemicLactic acidosis
PhenacetinNon-narcotic analgesicChronic interstitial nephritis
PhenytoinAnticonvulsantAcute interstitial nephritis, diabetes insipidus
ProbenecidUricosuricCrystal nephropathy, nephrotic syndrome
PuromycinAntimicrobialNephrotic syndrome
QuinineMuscle relaxantThrombotic microangiopathic
QuinolonesAntimicrobialAcute interstitial nephritis, crystal nephropathy
RifampinAntimicrobialAcute interstitial nephritis
RanitidineGastrointestinalAcute interstitial nephritis
StatinsLipid- loweringRhabdomyolysis
SulfonamidesAntimicrobialAcute interstitial nephritis, crystal nephropathy
TacrolimusImmunosuppressiveAcute tubular necrosis
TetracyclineAntimicrobialAcute tubular necrosis
azidesDiureticAcute interstitial nephritis
TolbutamideHypoglycemicNephrotic syndrome
VancomycineAntimicrobialAcute interstitial nephritis

The information in this table has been obtained from numerous literature sources. For additional information on specific drugs, readers should consult the primary literature.

Aminoglycoside antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), contrast agents, and angiotensin converting enzyme inhibitors (ACEIs) are the most common cause of AKI in hospitalized patients (2). The risk of contrast-induced nephropathy is highest in diabetics and chronic kidney disease diabetes (9). “Drugs can cause nephrotoxicity by altering intraglomeu- lar hemodynamics and decreasing GFR (ACEI, angiotensin-converting enzyme blockers [ARBs], NSAID, cyclo- sporine, and tacrolimus) (10-15).” “Certain drugs such as ampicillin, ciprofloxacin, sulfon- amides, acyclovir, ganciclovir, methotrexate and triam- terene are associated with crystal nephropathy (16,17). Crystal nephropathy may also results from the use of che- motherapy due to uric acid and calcium phosphate crystal deposition (16,17).” “Statins and alcohol may induce rhabdomyolysis because of a toxic effect on myocyte function, or (18-20). Drugs most often associated with thrombotic microangiopathy include antiplatelet agents (e.g., cyclosporine, mitomycin- C, and quinine (21,22).” Drugs associated with tubular cell toxicity and acute in- terstitial nephropathy include aminoglycosides, ampho- tericin B, cisplatin, beta lactams, quinolones, rifampin, sulfonamides, vancomycin, acyclovir, and contrast agents (4,10,11). These agents induce renal tubular cell injury by impairing mitochondrial function and interfering with tubular transport and increasing oxidative stress and free radicals (6,10). Chronic use of acetaminophen, aspirin, di- uretics and lithium is associated with chronic interstitial nephritis leading to fibrosis and renal scarring (11,20-23).

Patient-related risk factors

Drug-induced renal disorders are more common in certain patients and in specific clinical situations. Infants and young children with extracellular volume depletion, sepsis, renal impairment, cardiovascular disease, diabetes, or prior exposure to radio contrast agents are at risk of developing drug nephrotoxicity.

Prevention strategies

Preventive strategies should target the safety of prescribing drug, monitoring their potential nephrotoxicity, correcting risk factors for nephrotoxicity. Before initiation the drug therapy, ensure adequate hydration and avoid the use of nephrotoxic drugs whenever possible (23-25). Correct intravascular depletion to maintain renal perfusion before initiation of nephrotoxic agents (24,26). Administer drug orally and use the lowest effective dose and shortest duration of therapy whenever possible (27,28). Maintain drug levels within the recommended therapeutic range. Use less toxic analgesics with the lowest prostaglandins activity such as acetaminophen in patients with chronic pain and limit the duration of therapy. Discontinue or reduce the dose of nephrotoxic drug with the first sign of toxicity. Monitor renal function and serum drug concentrations during drug therapy. Use the lowest dose of low osmolar contrast agent in patients with pre-existing renal insufficiency, heart failure, and diabetes. Ensure adequate hydration with normal saline or sodium bicarbonate infusion. Consider acetazolamide and monitor GFR 24-48 hours post exposure (26). The information in this table has been obtained from numerous literature sources. For additional information on specific drugs, readers should consult the primary literature.

Estimate of renal function

As a general rule, when a new drug is prescribed, baseline renal function should be evaluated before initiating the nephrotoxic medication. Close monitoring of renal function is also essential during the course of therapy. There are several ways to estimate GFR in children. One of the easiest and more practical one is Schwartz formula using the following formula (27): GFR (ml/min/1.73 m2) = Length (cm) × k/serum creatinine (mg/dL) k = 0.35 (infants 1-4 weeks) k= 0.45 (4-52 weeks) k = 0.55 (children 1-13 years) k = 0.55 (girls 14-17 years) k = 0.70 (boys 14-18 years) Correct intravascular depletion to maintain renal perfusion before initiation of nephrotoxic agents (24). Use analgesics with less prostaglandin activity such as aspirin and acetaminophen. Monitor renal function and serum drug concentrations during drug therapy and use the lowest effective dose and the shortest duration of therapy whenever possible (27,28).

Authors’ contribution

All authors contributed equally to the paper.

Conflicts of interest

The authors declared no competitive interests.

Ethical considerations

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support

None.
  26 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Risk prediction of contrast-induced nephropathy.

Authors:  Peter A McCullough; Andy Adam; Christoph R Becker; Charles Davidson; Norbert Lameire; Fulvio Stacul; James Tumlin
Journal:  Am J Cardiol       Date:  2006-02-23       Impact factor: 2.778

3.  Assessing kidney function--measured and estimated glomerular filtration rate.

Authors:  Lesley A Stevens; Josef Coresh; Tom Greene; Andrew S Levey
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

4.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

Review 5.  How to prevent, recognize, and treat drug-induced nephrotoxicity.

Authors:  Xiaoqing Guo; Chike Nzerue
Journal:  Cleve Clin J Med       Date:  2002-04       Impact factor: 2.321

6.  Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.

Authors:  Carlo Briguori; Flavio Airoldi; Davide D'Andrea; Erminio Bonizzoni; Nuccia Morici; Amelia Focaccio; Iassen Michev; Matteo Montorfano; Mauro Carlino; John Cosgrave; Bruno Ricciardelli; Antonio Colombo
Journal:  Circulation       Date:  2007-02-19       Impact factor: 29.690

7.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Authors:  David J Graham; Judy A Staffa; Deborah Shatin; Susan E Andrade; Stephanie D Schech; Lois La Grenade; Jerry H Gurwitz; K Arnold Chan; Michael J Goodman; Richard Platt
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

Review 8.  Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.

Authors:  Michael B Davidson; Snehal Thakkar; John K Hix; Naveen D Bhandarkar; Alan Wong; Martin J Schreiber
Journal:  Am J Med       Date:  2004-04-15       Impact factor: 4.965

Review 9.  Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Authors:  Ana L Huerta-Alardín; Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2004-10-20       Impact factor: 9.097

10.  Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting.

Authors:  Shawn M Manor; Gregory S Guillory; Suresh P Jain
Journal:  Pharmacotherapy       Date:  2004-05       Impact factor: 4.705

View more
  27 in total

Review 1.  Mechanisms of antimicrobial-induced nephrotoxicity in children.

Authors:  Kevin J Downes; Molly Hayes; Julie C Fitzgerald; Gwendolyn M Pais; Jiajun Liu; Nicole R Zane; Stuart L Goldstein; Marc H Scheetz; Athena F Zuppa
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

2.  Unique Transcriptional Programs Identify Subtypes of AKI.

Authors:  Katherine Xu; Paul Rosenstiel; Neal Paragas; Christian Hinze; Xiaobo Gao; Tian Huai Shen; Max Werth; Catherine Forster; Rong Deng; Efrat Bruck; Roger W Boles; Alexandra Tornato; Tejashree Gopal; Madison Jones; Justin Konig; Jacob Stauber; Vivette D'Agati; Hediye Erdjument-Bromage; Subodh Saggi; Gebhard Wagener; Kai M Schmidt-Ott; Nicholas Tatonetti; Paul Tempst; Juan A Oliver; Paolo Guarnieri; Jonathan Barasch
Journal:  J Am Soc Nephrol       Date:  2016-12-27       Impact factor: 10.121

Review 3.  Prevention and Management of AKI in ACS Patients Undergoing Invasive Treatments.

Authors:  Ravi A Thakker; Aiham Albaeni; Haider Alwash; Syed Gilani
Journal:  Curr Cardiol Rep       Date:  2022-08-04       Impact factor: 3.955

4.  Renal Impairment Associated With Trimethoprim-Sulfamethoxazole Use in the Pediatric Population.

Authors:  Caroline M Sierra; Yen Tran; Lacey Oana; Khaled Bahjri
Journal:  J Pediatr Pharmacol Ther       Date:  2022-09-26

5.  Use of the Capture-Recapture Method to Estimate the Frequency of Community- and Hospital-Acquired Drug-Induced Acute Kidney Injuries in French Databases.

Authors:  Amayelle Rey; Valérie Gras; Julien Moragny; Gabriel Choukroun; Kamel Masmoudi; Sophie Liabeuf
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

6.  Early Initiation of Oral Antihypertensives Reduces Intensive Care Unit Stay and Hospital Cost for Patients with Hypertensive Intracerebral Hemorrhage.

Authors:  Zhu Zhu; Matthew Bower; Sara Stern-Nezer; Steven Atallah; Dana Stradling; Leonid Groysman; Cyrus K Dastur; Yama Akbari; Wengui Yu
Journal:  Neurocrit Care       Date:  2020-06       Impact factor: 3.210

7.  A well plate-based multiplexed platform for incorporation of organoids into an organ-on-a-chip system with a perfusable vasculature.

Authors:  Benjamin Fook Lun Lai; Rick Xing Ze Lu; Locke Davenport Huyer; Sachiro Kakinoki; Joshua Yazbeck; Erika Yan Wang; Qinghua Wu; Boyang Zhang; Milica Radisic
Journal:  Nat Protoc       Date:  2021-03-31       Impact factor: 13.491

Review 8.  Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges.

Authors:  Arash Aghajani Nargesi; Lilach O Lerman; Alfonso Eirin
Journal:  Stem Cell Res Ther       Date:  2017-12-04       Impact factor: 6.832

9.  Mesenchymal Stem Cells Attenuate Cisplatin-Induced Nephrotoxicity in iNOS-Dependent Manner.

Authors:  Bojana Simovic Markovic; Marina Gazdic; Aleksandar Arsenijevic; Nemanja Jovicic; Jovana Jeremic; Valentin Djonov; Nebojsa Arsenijevic; Miodrag L Lukic; Vladislav Volarevic
Journal:  Stem Cells Int       Date:  2017-07-30       Impact factor: 5.443

Review 10.  Immunomodulatory Effects of Mesenchymal Stem Cells on Drug-Induced Acute Kidney Injury.

Authors:  Qiuxia Han; Xiaochen Wang; Xiaonan Ding; Jun He; Guangyan Cai; Hanyu Zhu
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.